亚洲人群胰高糖素样肽-1受体激动剂应用的真实世界证据  

Real World Evidence for Application of Glucagon-like Peptide-1 Receptor Antagonist in Asian Population

作　　者：张倩[1] 谷伟军[2] ZHANG Qian;GU Wei-jun(Department of Endocrinology,the Seventh Medical Center of Chinese PLA General Hospital,Beijing 100700,China;Department of Endocrinology,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院第七医学中心内分泌科,北京100700 [2]解放军总医院第一医学中心内分泌科,北京100853

出　　处：《药品评价》2020年第S01期38-42,共5页Drug Evaluation

摘　　要：近几年多种新型降血糖药物密集上市,随机对照试验(randomized controlled trial,RCT)显示这些药物在降低血糖和糖化血红蛋白(glycosylated hemoglobin,HbA1C)以及改善远期预后方面均优于传统的口服药物和胰岛素。胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RA)是近些年亚洲区域主要使用的新型降血糖药物种类之一,其中以利拉鲁肽和度拉糖肽应用最为广泛。除随机对照试验(randomized controlled trial,RCT)之外,亚洲区域也积累了一些真实世界研究结果,很大程度上补充了RCT作为循证医学证据的不足。本文就亚洲人群使用GLP-1 RA的相关证据做一综述。In recent years,many kinds of novel anti-diabetic drugs(ADD)have been approved to be applied in clinical practice.Randomized controlled trials(RCTs)have demonstrated the efficacy and safety of these new drugs of at least three aspects:reduction of blood glucose and HbA1c,long-term prognosis which are all superior to traditional ADD.Glucagon-like peptide-1 receptor antagonist(GLP-1 RA)has been used worldwide for many years especially in Asian district.Many real-world studies have been published in recent years and provide sufficient evidence to support the application of GLP-1 RA in Asian population.

关 键 词：胰高糖素样肽-1受体激动剂 利拉鲁肽 度拉糖肽 真实世界研究 

分 类 号：R587.1[医药卫生—内分泌]